We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+16.37%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$26.2M
Cap. Flow
+$45.7M
Cap. Flow %
10.38%
Top 10 Hldgs %
36.84%
Holding
138
New
52
Increased
12
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$10.8M
2
INSM icon
Insmed
INSM
+$9.42M
3
BBIO icon
BridgeBio Pharma
BBIO
+$6.93M
4
APLS
Apellis Pharmaceuticals
APLS
+$5.77M
5
BCYC
Bicycle Therapeutics
BCYC
+$5.19M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$18.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.97M
4
BHVN icon
Biohaven
BHVN
+$6.93M
5
ETNB
89bio
ETNB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 53.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABOS icon
76
Acumen Pharmaceuticals
ABOS
$155M
$1.04M 0.23%
254,945
– –
PNT
77
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.01M 0.23%
139,565
– –
KOD icon
78
Kodiak Sciences
KOD
$2.6B
$1.01M 0.23%
+162,527
New +$1.14M
PRQR icon
79
ProQR Therapeutics
PRQR
$243M
$1.01M 0.23%
472,625
+50,000
+12% +$153K
IVA
80
Inventiva
IVA
$1.06B
$999K 0.23%
+292,599
New +$1.55M
ACHV icon
81
Achieve Life Sciences
ACHV
$659M
$990K 0.22%
+174,714
New +$830K
IMUX icon
82
Immunic
IMUX
$190M
$969K 0.22%
65,000
– –
OKUR
83
OnKure Therapeutics
OKUR
$154M
$932K 0.21%
15,582
– –
KRYS icon
84
PUT
Krystal Biotech
KRYS
$10.1B
$825K 0.19%
10,300
-155,600
-94% -$12.2M
TYRA icon
85
Tyra Biosciences
TYRA
$1.9B
$774K 0.18%
+48,170
New +$573K
SAGE
86
DELISTED
Sage Therapeutics
SAGE
$747K 0.17%
17,805
-50,000
-74% -$2.15M
VKTX icon
87
Viking Therapeutics
VKTX
$3.7B
$719K 0.16%
43,156
-160,000
-79% -$1.65M
LYRA
88
DELISTED
LYRA THERAPEUTICS INC
LYRA
$711K 0.16%
6,874
– –
COGT icon
89
Cogent Biosciences
COGT
$6.65B
$677K 0.15%
62,766
– –
BCLI
90
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$627K 0.14%
12,662
– –
BHVN icon
91
CALL
Biohaven
BHVN
$2.03B
$617K 0.14%
+45,200
New +$719K
TARA icon
92
Protara Therapeutics
TARA
$220M
$585K 0.13%
188,664
– –
IMTX icon
93
Immatics
IMTX
$1.18B
$526K 0.12%
179,552
+130,521
+266% +$1.07M
ELDN icon
94
Eledon Pharmaceuticals
ELDN
$261M
$524K 0.12%
221,830
– –
AUTL
95
Autolus Therapeutics
AUTL
$397M
$479K 0.11%
260,087
– –
ASLN
96
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$476K 0.11%
20,511
– –
PTCT icon
97
CALL
PTC Therapeutics
PTCT
$5.68B
$475K 0.11%
+9,800
New +$448K
ANEB
98
DELISTED
Anebulo Pharmaceuticals
ANEB
$462K 0.1%
156,203
– –
IMGN
99
CALL
DELISTED
Immunogen Inc
IMGN
$409K 0.09%
+106,600
New +$454K
CMMB
100
Chemomab Therapeutics
CMMB
$11.4M
$342K 0.08%
59,177
-19,171
-24% -$150K
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Ikarian Capital held 138 positions worth $441M, up 6.3% from $415M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital deployed $45.7M of net new capital in Q1 2023, opening 52 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 100,000 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 58% a quarter earlier.

On the sell side, the largest reduction was Prometheus Biosciences, Inc. Common Stock, an estimated $18.8M trimmed.

  • Ikarian Capital's largest Q1 2023 buy was Merck: 100,000 shares worth $10.6M.
  • Ikarian Capital added most to Altimmune in Q1 2023, an estimated $4.8M increase.
  • Ikarian Capital's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $18.8M.
  • Ikarian Capital fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $10.2M.
  • Ikarian Capital's ten largest holdings make up 37% of its $441M portfolio in Q1 2023.
  • Ikarian Capital opened 52 new positions and closed 21 in Q1 2023.
  • Ikarian Capital's portfolio value rose 6.3% quarter-over-quarter to $441M.

Based on Ikarian Capital's 13F filing for Q1 2023, filed 15 May 2023.